



Medicines & Healthcare products  
Regulatory Agency



Caroline Blackwell,  
Managing Secretary,  
Editorial Office,  
Reproductive Biomedicine Online,  
Elsevier Inc.,

**National Institute for Biological  
Standards and Control**

Blanche Lane  
South Mimms  
Potters Bar  
Hertfordshire EN6 3QG

**[www.nibsc.org](http://www.nibsc.org)**

15 March 2018

Dear Ms Blackwell,

RBMO-D-17-00704

Towards International Standardization of Immunoassays for Mullerian Inhibiting Substance/Anti-Mullerian Hormone

Thank you for your email dated 08 March 2018 noting the addition of two new authors to this publication. An essential characteristic of a WHO International Standard is that it exhibits long term stability which is achieved through lyophilization. For AMH, considerable development work was required to identify a suitable formulation and lyophilization conditions. For this, we were reliant on knowledge and technical skills of Dr Paul Matejtschuk and Chinwe Duru to identify and successfully freeze dry the material such that immunoreactivity was maintained. Identification of the optimum conditions was not straight-forward and the original authors are in agreement that the contribution of Dr Matejtschuk and Ms Duru were essential to the aim of the study and to progress towards the development of an International Standard for AMH.

Please do not hesitate to contact me with any further queries.

Yours sincerely,

Jackie Ferguson  
Senior Scientist, Biotherapeutics

T 01707 641135

E [Jackie.ferguson@nibsc.org](mailto:Jackie.ferguson@nibsc.org)